

%201.webp)


%201.webp)




LSPedia 的全球序列化系列
序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
欢迎来到 LspEdia,在这里,创新与奉献精神相结合。
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。



%201.webp)


%201.webp)




序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。

China has developed a national drug traceability framework under the NMPA and the broader regulatory reform embedded in the Drug Administration Law (effective 1 December 2019), requiring serialized identification of pharmaceutical products and traceability of supply chain movements. Though the Chinese system differs in format and rollout timing from GS1-based systems elsewhere, the direction is clear: each pack must carry a trace-code; distributors and pharmacies must capture and report key events; and from 2025 onward full traceability links with the national insurance reimbursement system will enforce compliance.
We invite you to learn more about how LSPedia can support your compliance and supply chain needs. For more information about our solutions, partnership opportunities, or to speak with one of our experts.